HomeIndustriesHealthcareMoser: Small Cap Outperformance in 2026, Likes Biotech Including PCRX, SIBN

Moser: Small Cap Outperformance in 2026, Likes Biotech Including PCRX, SIBN

Nathan Moser, Sr. expects GDP to surprise to the upside next year and makes the bull case for U.S. small caps. He especially sees opportunities in biotech and shares several picks, including Pacira Biosciences (PCRX) and SI-Bone (SIBN). “Many of the great medtech companies are eventually acquired,” he notes as well.

Trading 360

31 Dec 2025

SHARE

ON AIR
2:00 pm
Market On Close
12:00 am
The Wrap
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
ON AIR
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Schwab 2026 Outlook
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Schwab 2026 Outlook
REPLAY
11:00 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor